

## Original Research

### Clinical Characteristics and Health Care Resource Utilization Among Individuals Undergoing Alpha-1 Antitrypsin Testing in a Quaternary Health System

Drew D. Robinson, MD<sup>1,2,3</sup> Chia-Ying Chiu, DrPH<sup>1,2</sup> Jane I. Hampton, MD<sup>4</sup> George M. Solomon, MD<sup>1,5</sup> J. Michael Wells, MD, MSPH<sup>1,2,3,6</sup>

<sup>1</sup>Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States

<sup>2</sup>Lung Health Center, University of Alabama at Birmingham, Birmingham, Alabama, United States

<sup>3</sup>Alpha-1 Clinical Resource Center, University of Alabama at Birmingham, Birmingham, Alabama, United States

<sup>4</sup>Department of Pediatric Critical Care Medicine, Baylor College of Medicine, Houston, Texas, United States

<sup>5</sup>Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama Birmingham, Birmingham, Alabama, United States

<sup>6</sup>Birmingham VA Health Care System, Birmingham, Alabama, United States

#### ***Address correspondence to:***

Drew Robinson, MD  
University of Alabama at Birmingham  
Phone: (281) 683-6791  
Email: ddrobinson@uabmc.edu

#### ***Running Head: AATD Testing in a Large Health System***

***Keywords:*** alpha-1 antitrypsin deficiency; forced expiratory volume in 1 second; forced vital capacity; health care utilization; patient characteristics

***Abbreviations:*** Alpha-1 Antitrypsin (AAT), Alpha-1 antitrypsin deficiency (AATD), complete blood count (CBC), chronic obstructive pulmonary disease (COPD), electronic health record (EHR), forced expiratory volume in 1-second (FEV1), mean FEV1 percent predicted (FEV1pp), FEV1 to forced vital capacity (FEV1/FVC), heterozygotes (het), Intensive Care Unit (ICU), isoelectrofocusing (IEF), liver function tests (LFTs), Neutrophil lymphocyte ratio (NLR), Polymerase Chain Reaction (PCR), Pulmonary Function Testing (PFT),

**Funding Support:** None

**Date of Acceptance:** March 15, 2026 | **Published Online Date:** March 30, 2026

**Citation:** Robinson DD, Chiu CY, Hampton JI, Solomon GM, Wells JM. Clinical characteristics and health care resource utilization among individuals undergoing alpha-1 antitrypsin testing in a quaternary health system. *Chronic Obstr Pulm Dis*. 2026; Published online March 30, 2026.

<https://doi.org/10.15326/jcopdf.2025.0723>

Pre-proof

## Abstract

### Rationale

Alpha-1 antitrypsin deficiency (AATD) is a genetically inherited condition that can result in serious lung and liver disease. It is unclear whether testing for common alleles is sufficient or if testing for rare variants is helpful in identifying clinically significant disease.

### Methods

A retrospective review was performed on adult patients who had AAT phenotyping from January 2016 through December 2021. We recorded clinical characteristics and then grouped patients based on PI\*types: Normal, PI\*Z-heterozygotes (het), PI\*ZZ, PI\*S-hets, and defined a PI\*Non-S/Non-Z group to include other identified PI\*types. Chi Square and Kruskal-Wallis tests were used for bivariate analyses, generalized linear models for modeling forced expiratory volume in 1-second (FEV1), and logistic regression modeling for healthcare utilization outcomes adjusted for race, age, and sex.

### Results

1,772 tests were ordered from January 2016 through December 2021. Testing identified 79.5% Pi\*MM, 8.4% PI\*Z-het, 8.4% Pi\*S-het, 3.3% PI\*Non-S/Non-Z, and 0.5% PI\*ZZ. FEV1 to forced vital capacity (FEV1/FVC) and FEV1 percent predicted were lowest in the PI\*Non-S/Non-Z group compared to the other groups. PI\*Non-S/Non-Z group had higher mean neutrophil lymphocyte ratio (NLR) compared to the other groups ( $p=0.021$ ), higher hospitalization for acute respiratory events (27.6%;  $p=0.019$ ), ICU utilization (15.3%,  $p=0.011$ ) and death (25.4%,  $p=0.041$ ) compared to the other groups.

### Conclusions

AATD PI\*typing identified several allelic combinations not previously linked with clinical disease. Compared to other PI\*type groups, PI\*‘Non-S/Non-Z’ group had impairments in pulmonary function, elevated inflammatory markers, higher health care utilization, and death. Our results underpin the need to explore relationships between rare allelic combinations and clinical outcomes.

**Introduction:**

Alpha-1 antitrypsin deficiency (AATD) is a genetically inherited condition that is the result of a mutation in the SERPIN1A gene, located on the long arm of chromosome 14 at 14q32.1, which leads to misfolding or absence of the anti-protease alpha-1-antitrypsin (AAT) protein (1-3). Accumulation of misfolded protein leads to liver degradation and insufficient degradation of proteases causing loss of function lung disease, leading to cirrhosis and emphysema, respectively (1, 2). The clinical consequences of ZZ, SZ, and MZ phenotypes are well described (1, 2). Many other variant alleles exist, but literature is scarce on the clinical significance of these mutations (1, 4). Despite clear recommendations for screening, AATD remains overwhelmingly underdiagnosed with AATD being diagnosed in <10% of those expected based on screening studies (1, 3-8). Delays in diagnosis are also common, taking up to 8.8 years from the time of symptom onset to AATD diagnosis(8). Clinical pathways and processes for AATD testing have been proposed as a means to improve screening for AATD. It is unclear how order sets to test for AATD in clinical practice will influence AATD screening and if testing for variants other than M, S, and Z provides additional utility in identifying clinically significant disease (3, 6).

**Methods:**

We conducted a retrospective review on all adult patients who had AAT PI-typing using isoelectrofocusing (IEF, Quest Diagnostics), performed from January 2016 through December 2021 in the University of Alabama at Birmingham (UAB) Health System. This test was used for several reasons, including its availability to clinical providers and ease of incorporation into order sets in the Health System (e.g., hepatology clinic order set, chronic obstructive pulmonary disease [COPD] exacerbation order set). We recorded ordering location (pulmonary, hepatology, other), AAT PI\*type results, AAT levels, age, sex, race, body mass index (BMI), smoking status, comorbidities (including COPD, asthma, bronchiectasis, cirrhosis), therapies including supplemental oxygen use and augmentation therapy use, spirometry values (including forced expiratory volume in 1-second [FEV1], forced vital capacity [FVC], and FEV1/FVC), laboratory data (liver function tests [LFTs], complete blood count [CBC], immunoglobulins). Health care utilization events of interest included outpatient visits for acute respiratory exacerbations, hospitalization for respiratory exacerbations, intensive care unit (ICU) utilization; vital status was recorded for death from any cause after a PI\*Type was ordered. We then divided the cohort

into the following groups based on the results of AAT testing: Normal (PI\*MM, PI\*M1M2, PI\*MZ Pratt), PI\*Z-heterozygotes (het) (PI\*MZ, PI\*SZ, PI\*IZ, PI\*FZ), PI\*ZZ, PI\*S-het (PI\*S?,PI\*SS, PI\*MS, PI\*CS), and defined a PI\*Non-S/Non-Z group that included other identified PI\*types (PI\*BM, PI\*CM, PI\*DM, PI\*EM, PI\*FM, PI\*GM, PI\*LM, PI\*M1N, PI\*MT). Chi Square and Kruskal-Wallis tests were used for analyses in SAS 9.4. We used generalized linear models for modeling FEV1 percent predicted with PI\*Type by smoking status. Logistic regression was utilized to measure associations between PI\*Type and outcomes of hospitalization, ICU admission, and death with race, age, and sex. This study was approved by the Institutional Review Board at the University of Alabama at Birmingham (UAB IRB-300006077).

### Results:

A total of 1,772 tests were ordered from January 2016 through December 2021 in the University of Alabama at Birmingham Healthcare System. AAT PI\*type testing increased each year from 129 tests in 2018 to 613 in 2021. Most tests were ordered by hepatology and pulmonary services (**Figure 1**). A total of 530 tests (29.96%) were ordered by pulmonary and 1068 tests (60.4%) were ordered by hepatology. Of the 1,777 tests ordered, 1,772 had phenotype/Pi\*type results (99.7%) and 1,135 (63.9%) had AAT levels ordered.

The cohort was grouped by PI\*type as follows: 79.5% normal, 8.4% PI\*Z-het, 8.4% Pi\*S-het, 3.3% PI\*Non-S/Non-Z, and 0.5% PI\*ZZ (**Figure 1, Table 1**). Our PI\*Non-S/Non-Z cohort was composed of (PI\*BM (1/59 (1.7%)), PI\*CM (31/59 (52.5%)), PI\*DM (1/59 (1.7%)), PI\*EM (5/59 (8.5%)), PI\*FM (8/59 (13.6%)), PI\*GM(8/59 (13.6%)), PI\*LM(1/59(1.7%)), PI\*M1N(1/59 (1.7%)), and PI\*MT(3/59 (5.1%)) (**Table 2**). We then characterized the individuals with any abnormal PI\*type (n=364) identified by testing. As detailed in **Table 1**, individuals with any abnormal PI\*type included in the cohort were 61±15 years old, 47.5% male, 89.3% White race, 6.3% Black race, and 4.4% other race [Asian (0.8%), Hispanic (0.8%), other/unknown/refuse to answer/missing (2.8%)]. More than half (55.3%) of the cohort were never smokers, 30.4% were former smokers, and 14.2% were current smokers. Liver disease was present in 69.5% and COPD was present in 21.6%. Age, sex, BMI, smoking status, and asthma diagnosis were similar across groups. We observed a higher proportion of Black race in the PI\*Non-S/Non-Z cohort (n=11, 18.6%) compared to other groups (PI\*Z-het (n=3, 2.0%); PI\*S-

het (n=9,6.1%); PI\*ZZ (n=0, 0%);  $p<0.0001$ ). In our Non-S/Non-Z cohort, 8/11 of those with Black race were PI\*CM phenotype, 2/11 were PI\*EM, and 1/11 were PI\*GM (**Table 2**). As detailed in **Table 1**, we observed differences in COPD prevalence by PI\*type ( $P=0.03$ ), but did not observe between-group differences in other key comorbid conditions including bronchiectasis ( $P=0.54$ ), abnormal liver function tests ( $P=0.35$ ), and cirrhosis ( $P=0.96$ ).

Next, we evaluated laboratory and physiological measures in the various PI\*Types. The mean FEV1 percent predicted (FEV1pp) is statistically different among PI\*types with the lowest in the PI\*Non-S/Non-Z group ( $55.8\pm 24.5\%$ ) followed by PI\*ZZ ( $65.8\pm 29.3\%$ ), PI\*S-het ( $72.1(\pm 19.7)$ ), and PI\*Z-het ( $75.3\pm 23.5\%$ )  $P=0.0086$ . We then stratified lung function by smoking status. Not unexpectedly, FEV1pp was lowest among current smokers and highest in never smokers in the full cohort ( $p=0.0002$ ). Of note, there were no active smokers in the PI\*ZZ phenotype. As shown in **Figure 2**, we found that FEV1 was lowest in PI\*Non-S/Non-Z in current smokers ( $P=0.0001$ ), but FEV1/FVC values were similar across PI\*type groups in current or former smokers.

Mean AAT levels were lowest in the PI\*ZZ group (13.0 mg/dl; n=1/8) and PI\*Z-het group ( $93.7\pm 29.9$  mg/dl; n=111/149) but were otherwise similar across the other groups: PI\*Non-S/Non-Z group ( $149.6\pm 52.4$  mg/dl; n=28/59), PI\*S-het ( $134.5\pm 35.0$  mg/dl; n=92/148), and normal group ( $159.0\pm 39.1$  mg/dl; n=903/1408). We compared values of routinely measured inflammatory markers by PI\*type. While there was no significant difference in White Blood Cell (WBC) values (PI\*Non-S/Non-Z group ( $7.1\pm 3.0$ ), PI\*Z-het ( $6.4\pm 2.1$ ), PI\*S-het ( $6.7\pm 2.0$ ), and PI\*ZZ groups ( $6.0\pm 1.94$ ) ( $p=0.3578$ ), mean neutrophil lymphocyte ratio (NLR) was highest in the PI\*Non-S/Non-Z group ( $4.9\pm 5.0$ ) compared to the PI\*Z-het ( $3.0\pm 2.0$ ), PI\*S-het ( $3.0\pm 2.0$ ), and PI\*ZZ groups ( $2.4\pm 0.9$ ) ( $p=0.021$ ). There were no significant differences in immunoglobulin levels across subgroups.

We then measured healthcare utilization and outcomes across abnormal PI\*types. Patients in the PI\*Non-S/Non-Z group had higher incidence of hospitalization for acute respiratory events (27.6%) compared to PI\*Z-het (10.2%), PI\*S-het (14.4%), and PI\*ZZ (14.3%) ( $p=0.018$ ) as well as higher ICU utilization ( $p=0.011$ ) and death ( $p=0.041$ ) compared to the other groups (**Figure 3**). In order to control for confounders, we next used logistic regression analysis on the outcomes of ICU utilization, hospitalization, and mortality adjusted for age, race, sex, smoking status, and cirrhosis diagnosis. We observed an increase in odds of hospitalization (OR

1.88, 95%CI 0.85-4.18) as well as ICU utilization (OR 1.53, 95%CI 0.56-4.16) in the Non-S/Non-Z group compared to PI\*S-het group although the associations do not reach a statistical significance. Mortality was elevated in the Non-S/Non-Z group compared to PI\*S-het (OR 3.31, 95%CI 1.41-7.76). There were similar relationships when comparing between group differences between black or non-black populations when adjusted for age, race, sex, smoking status, and cirrhosis diagnosis on the outcomes of hospitalization (OR 1.95, 95%CI 0.89-4.27), ICU admission (OR 1.53, 95%CI 0.57-4.10), or mortality (OR 3.06, 95%CI 1.32-7.11).

### **Discussion:**

We observed rates of testing for AATD using PI\*typing increased substantially over time within a quaternary health care system, and uncommon mutations were associated with clinically relevant outcomes. Our findings emphasize the importance of testing for AATD and that detection of clinically significant AATD disease phenotypes are under-recognized. The increase in testing over time in our health system was largely due to implementation of AAT screening into commonly used electronic health record (EHR) order sets developed as part of process improvements for new patients being evaluated by the hepatology clinic and in the COPD exacerbations order set starting in 2019. Multiple prior attempts to increase AATD testing have been proposed by others in the past with varying results, but our findings suggest there is work still to be done (9-12). In 2020, there was a decrease in the number of orders, likely related to the COVID-19 pandemic, as the number of testing increased again in 2021.

In parallel with the increase in tests performed, we observed an increased number of abnormal alleles and were able to identify a group of non-S, non-Z individuals we designated as a PI\*Non-S/Non-Z group. The low number of observations of the non-S, non-Z PI\*types are not surprising and are consistent with previously reported rates (13). This PI\*Non-S/Non-Z group, despite being composed of heterogeneous PI\*types, had clinically meaningful markers of disease severity including lower FEV1, higher rates of hospitalization for respiratory events, higher ICU utilization, and death during the time period of our study compared to other PI\*type groups, signifying a potential clinical association more substantial than what has been previously recognized (13). This PI\*Non-S/Non-Z group also had a higher neutrophil to lymphocyte ratio (NLR), suggesting a potential heightened inflammatory state in this group (14). A higher NLR is associated with indices of COPD disease severity and is predictive for COPD exacerbations (15).

Higher NLR in the PI\*Non-S/Non-Z cohort may explain the higher rates of respiratory event hospitalization and ICU admission, though these results need to be confirmed.

Although modeling has not identified associations between these ‘Non-S/Non-Z’ PI-types and either anti-neutrophil elastase activity or misfolding, these data suggest the possibility that rare AAT mutations could influence disease risks through other mechanisms (13, 16-20). One consideration could be altered regulation of inflammation, supported by the higher NLR in this cohort (14). Another consideration for the observed differences in clinical outcomes by race and PI\*Type suggest that social determinants of health may also play a role. The fact that nearly 20% of the PI\*Non-S/Non-Z group was Black race is an important observation. The most common Non-S/Non-Z variant was PI\*CM (52%) and this variant had a higher proportion of Black race (72% of the Black race patients with the Non-S/Non-Z phenotype had the PI\*CM variant). Given the higher proportion of black patients with PI\*CM variant, future studies should explore these associations in a prospective manner. The exact implications for this finding are unclear, but it reinforces the need to test all individuals at risk for AATD, regardless of race. Many patients would not have been diagnosed if not for IEF testing. Therefore, performing phenotyping rather than simple genetic screening and obtaining levels may be important for those populations known to have lower AATD prevalence, particularly in those without risk factors such as cirrhosis or COPD. Black individuals are a population known to have proportionally lower AATD testing compared to other genetic ancestry groups (21). Recently, Riley and colleagues demonstrated that white race is a factor favoring increased AAT testing, and non-white race as having lower odds of AAT testing (22). By predominantly testing individuals with European ancestry, the medical community may be missing other populations at risk for adverse health outcomes.

Our observed testing practices prior to 2019 reflect previously reported findings, with pulmonologists ordering the most tests, followed by hepatologists, and then other specialties (primary care, surgery, etc.). For example, the National Detection Program for AATD, more than 580,000 individuals were assessed for AATD from 2003-2017 and pulmonologists were more likely than primary care providers to test for AATD (23). However, inclusion of AAT PI\*typing as part of a ‘new patient’ order set for chronic liver disease clinic, hepatology surpassed pulmonology as the service line that ordered the most AAT phenotype tests.

Over the six-year timeframe of our trial, we identified 8/364 (2.2%) PI\*ZZ individuals, which is similar to previously reported rates (9, 24). Several strategies have been proposed to improve testing for AATD, all with varying levels of success. Schumacher et al, used a web-based education module to improve awareness of AATD screening with a nearly doubled rate of high risk screening, including more than one fourth of those tested identified as AATD (17). EHR systems have been used in the past, with Choudry et al using the EHR database at two clinics to identify patients diagnosed with COPD and arrange AAT testing, with 109 patients coming for testing out of a total of 1247 COPD patients identified (12). Another study by Jain et al used their EHR to alert physicians to order AAT testing of patients with obstruction on Pulmonary Function Testing (PFT), with testing completed on 209 patients out of a total of 12,369 identified as eligible for testing(10). Using their EHR systems, these two studies were able to identify 1/109 (0.9%) and 1/46 (2.17%) patients with PI\*ZZ homozygote, respectively (10, 12). While using EHR systems and use of order sets are clearly helpful to increase testing, it is unknown if using EHR order sets will consistently identify phenotypes that will manifest clinically relevant disease.

There are many methods available for testing for AATD, including immunoassays (radial immunodiffusion, rocket immunoelectrophoresis, and nephelometry), phenotyping using thin-layer isoelectric focusing (IEF), and genotyping using either polymerase chain reaction (PCR) or sequencing of exonic DNA (25). While immunoassays are relatively cheap, they don't reliably detect heterozygotes (25). Our population was identified using IEF, but null variants cannot be not detected using this method, which is a limitation of the IEF approach. PI\*typing using IEF is advantageous for healthcare systems as it can detect an AAT allele without knowing the AAT level, but it is a manual technique which requires skills and appropriate standards for testing (25). Genotype testing has the advantage of being relatively inexpensive and definitive if using an available primer, but may miss rare variants unless using sequencing, which is expensive(25). Genotype testing is recommended as a first line testing method due to its ability to provide accurate and early identification of the traditional disease causing alleles (S or Z) followed by confirmatory AAT level testing and consideration of alternate testing (i.e., IEF) when there is a discordance between the level and genotype (26). Although genotype testing is recommended as first-line screening, our findings suggest that phenotyping should not be limited to having a discordance between the level and the genotype because almost all Non-S/Non-Z phenotypes

will have normal levels. If IEF testing were done for discordance between levels and genotype testing, only 2-3 patients would have been identified out of the 59 patients in this study and therefore an important group of patients would have gone unrecognized. One potential solution based on these findings would be to include the PI\*CM variant in genetic PCR testing because the majority of PI\*Non-S/Non-Z patients were the PI\*CM variant in our study. Health systems should be cognizant of these differences when selecting the appropriate test for their use case.

Our study is not without limitations. Most importantly is the single-center design and lack of a validation cohort. Additionally, given that the majority of testing for AATD was done in the hepatology clinic as part of diagnostic evaluation for liver disease, cirrhosis and abnormal liver function testing were likely overrepresented and therefore the results of our cohort may not be as applicable to the general AATD population. In fact, cirrhosis was more common (38.2%) in our cohort, compared to reported prevalence of cirrhosis in Pi\*ZZ AATD, which is typically just over 10% (27). Regardless of the high prevalence of concomitant liver disease in our cohort, cirrhosis was not significantly higher in the PI\*Non-S/Non-Z group compared to the other groups, so a finding of end-stage liver disease alone would not explain higher observed rates and numbers of hospitalization, ICU utilization, or death observed in the PI\*Non-S/Non-Z group. Our data is limited by the retrospective nature of the study and small numbers of PI\*ZZ genotypes. The small sample size and heterogeneous nature of the 'Non-S/Non-Z' grouping schema limit investigations into associations between individual rare allelic combinations and clinically relevant disease in this cohort. However, these findings present an opportunity for groups of clinicians and researchers in the alpha-1 community to collaborate to create research registries – like those that are done within the Alpha-1 Foundation (<https://alpha1.org>) or through the European Alpha-1 Research Collaboration (EARCO; <https://www.earco.org/>).

In summary, our experience of screening for AATD using PI\*phenotyping as part of an EHR-based order set increases the number of tests. This strategy not only identified individuals with severe AATD, but also recognized a heterogeneous group of non-S, non-Z individuals that are linked with relevant clinical outcomes. While these findings need to be replicated in future studies, our results underpin the need to explore relationships between rare allelic combinations and clinical outcomes.

Declaration of interest:

Drew Robinson, Chia-Ying Chiu, and Jane Hampton have no conflicts to declare.

George Marty Solomon reports receiving grants from the Cystic Fibrosis Foundation, NIH, COPD Foundation, PCD Foundation, Vertex, Electromed, Boeringer-Ingelheim, 4DMT, BIOMX, Astra-Zeneca, and Sanofi for work unrelated to the current manuscript; and has received honoraria for consulting work from Insmmed, Electromed, and Vertex for unrelated projects.

James Michael Wells reports grants and contracts to his institution from the NIH, Veterans Affairs, Medscape, Verona Pharma, and Sanofi; he has served as a consultant for AstraZeneca, Takeda, Bavarian Nordic, Krystal Biotech, Sanofi, and Verona Pharma for content outside the submitted work.

## References

1. Fromme M, Schneider CV, Trautwein C, Brunetti-Pierri N, Strnad P. Alpha-1 antitrypsin deficiency: A re-surfacing adult liver disorder. *J Hepatol.* 2022;76(4):946-58. Epub 20211127. doi: 10.1016/j.jhep.2021.11.022. PubMed PMID: 34848258.
2. Ferrarotti I, Carroll TP, Ottaviani S, Fra AM, O'Brien G, Molloy K, et al. Identification and characterisation of eight novel SERPINA1 Null mutations. *Orphanet J Rare Dis.* 2014;9:172. Epub 20141126. doi: 10.1186/s13023-014-0172-y. PubMed PMID: 25425243; PubMed Central PMCID: PMC4255440.
3. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. *Am J Respir Crit Care Med.* 2003;168(7):818-900. doi: 10.1164/rccm.168.7.818. PubMed PMID: 14522813.
4. Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. *N Engl J Med.* 2009;360(26):2749-57. doi: 10.1056/NEJMcp0900449. PubMed PMID: 19553648.
5. Stockley RA. Alpha-1 Antitrypsin Deficiency: The Learning Goes On. *Am J Respir Crit Care Med.* 2020;202(1):6-7. doi: 10.1164/rccm.202004-0922ED. PubMed PMID: 32343597; PubMed Central PMCID: PMC7328316.
6. Sandhaus RA, Turino G, Brantly ML, Campos M, Cross CE, Goodman K, et al. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. *Chronic Obstr Pulm Dis.* 2016;3(3):668-82. Epub 20160606. doi: 10.15326/jcopdf.3.3.2015.0182. PubMed PMID: 28848891; PubMed Central PMCID: PMC5556762.
7. McElvaney NG. Diagnosing  $\alpha$ 1-antitrypsin deficiency: how to improve the current algorithm. *Eur Respir Rev.* 2015;24(135):52-7. doi: 10.1183/09059180.10010814. PubMed PMID: 25726555; PubMed Central PMCID: PMC9487760.
8. Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with alpha1-antitrypsin deficiency between 1968 and 2003. *Chest.* 2005;128(3):1179-86. doi: 10.1378/chest.128.3.1179. PubMed PMID: 16162704.
9. Lam SW, Strange C, Brantly ML, Stoller JK. A Novel Detection Method to Identify Individuals with Alpha-1 Antitrypsin Deficiency: Linking Prescription of COPD Medications with the Patient-Facing Electronic Medical Record. *Chronic Obstr Pulm Dis.* 2022;9(1):26-33. doi: 10.15326/jcopdf.2021.0260. PubMed PMID: 34784453; PubMed Central PMCID: PMC8893965.
10. Jain A, McCarthy K, Xu M, Stoller JK. Impact of a clinical decision support system in an electronic health record to enhance detection of  $\alpha$ 1-antitrypsin deficiency. *Chest.* 2011;140(1):198-204. Epub 20101230. doi: 10.1378/chest.10-1658. PubMed PMID: 21193532.
11. Rahaghi FF, Sandhaus RA, Brantly ML, Rouhani F, Campos MA, Strange C, et al. The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction. *Copd.* 2012;9(4):352-8. Epub 20120416. doi: 10.3109/15412555.2012.669433. PubMed PMID: 22506682.
12. Choudry SA, Choudry AB, Lee MD. Alpha-1 Antitrypsin Genotype Screening In COPD Patient Identified Via EMR. C101 NEW INSIGHTS INTO ALPHA-1-ANTITRYPSIN DEFICIENCY AND OUTCOMES FOLLOWING COPD EXACERBATIONS. American Thoracic Society International Conference Abstracts: American Thoracic Society; 2011. p. A5353-A.
13. Bornhorst JA, Greene DN, Ashwood ER, Grenache DG.  $\alpha$ 1-Antitrypsin phenotypes and associated serum protein concentrations in a large clinical population. *Chest.* 2013;143(4):1000-8. doi: 10.1378/chest.12-0564. PubMed PMID: 23632999.

14. Günay E, Sarınc Ulaşlı S, Akar O, Ahsen A, Günay S, Koyuncu T, et al. Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: a retrospective study. *Inflammation*. 2014;37(2):374-80. doi: 10.1007/s10753-013-9749-1. PubMed PMID: 24078279.
15. Paliogiannis P, Fois AG, Sotgia S, Mangoni AA, Zinellu E, Pirina P, et al. Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives. *Eur Respir Rev*. 2018;27(147). Epub 20180207. doi: 10.1183/16000617.0113-2017. PubMed PMID: 29436405; PubMed Central PMCID: PMC9488932.
16. Akbas N, Gonzalez G, Buffone GJ, Grenache DG, Devaraj S. A Library of Rare  $\alpha$ 1-Antitrypsin (AAT) Variant Phenotypes to Aid in the Diagnosis of AAT Deficiency. *Am J Clin Pathol*. 2016;146(3):289-93. doi: 10.1093/ajcp/aqw112. PubMed PMID: 27543976.
17. Schumacher RC, Chiu CY, Lubarda J, Aboulsaoud P, Bomberger J, Wells JM. A Novel Provider Education Module to Enhance Detection of Alpha-1 Antitrypsin Deficiency. *ATS Sch*. 2023;4(4):490-501. Epub 20230817. doi: 10.34197/ats-scholar.2023-0028OC. PubMed PMID: 38196685; PubMed Central PMCID: PMC10773490.
18. Abboud RT, Nelson TN, Jung B, Mattman A. Alpha1-antitrypsin deficiency: a clinical-genetic overview. *Appl Clin Genet*. 2011;4:55-65. Epub 20110331. doi: 10.2147/tacg.S10604. PubMed PMID: 23776367; PubMed Central PMCID: PMC3681178.
19. Greene DN, Elliott-Jelf MC, Straseski JA, Grenache DG. Facilitating the laboratory diagnosis of  $\alpha$ 1-antitrypsin deficiency. *Am J Clin Pathol*. 2013;139(2):184-91. doi: 10.1309/ajcp6xbk8ulzxwfp. PubMed PMID: 23355203.
20. Graham RP, Dina MA, Howe SC, Butz ML, Willkomm KS, Murray DL, et al. SERPINA1 Full-Genome Sequencing Identifies Rare Mutations Not Detected in Targeted Mutation Analysis. *J Mol Diagn*. 2015;17(6):689-94. Epub 20150828. doi: 10.1016/j.jmoldx.2015.07.002. PubMed PMID: 26321041.
21. Lafortune P, Zahid K, Ploszaj M, Awadalla E, Carroll TP, Geraghty P. Testing Alpha-1 Antitrypsin Deficiency in Black Populations. *Adv Respir Med*. 2023;92(1):1-12. Epub 20231219. doi: 10.3390/arm92010001. PubMed PMID: 38392031; PubMed Central PMCID: PMC10886060.
22. Riley L, Sriram A, Brantly M, Lascano J. Testing Patterns and Disparities for Alpha-1 Antitrypsin Deficiency. *Am J Med*. 2023;136(10):1011-7. Epub 20230713. doi: 10.1016/j.amjmed.2023.06.020. PubMed PMID: 37451388.
23. Brantly M, Campos M, Davis AM, D'Armiento J, Goodman K, Hanna K, et al. Detection of alpha-1 antitrypsin deficiency: the past, present and future. *Orphanet J Rare Dis*. 2020;15(1):96. Epub 20200419. doi: 10.1186/s13023-020-01352-5. PubMed PMID: 32306990; PubMed Central PMCID: PMC7168939.
24. Blanco I, Diego I, Bueno P, Pérez-Holanda S, Casas-Maldonado F, Miravittles M. Prevalence of  $\alpha$ (1)-antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review. *Eur Respir Rev*. 2020;29(157). Epub 20200721. doi: 10.1183/16000617.0014-2020. PubMed PMID: 32699024; PubMed Central PMCID: PMC9489008.
25. Miravittles M, Herr C, Ferrarotti I, Jardi R, Rodriguez-Frias F, Luisetti M, et al. Laboratory testing of individuals with severe alpha1-antitrypsin deficiency in three European centres. *Eur Respir J*. 2010;35(5):960-8. doi: 10.1183/09031936.00069709. PubMed PMID: 20436173.
26. Hernandez P, Bosse Y, Bush P, Chapman KR, Maltais F, Penz ED, et al. Alpha-1-Antitrypsin Deficiency Targeted Testing and Augmentation Therapy: A Canadian Thoracic

Society Meta-Analysis and Clinical Practice Guideline. *Chest*. 2025;167(4):1044-63. Epub 20250127. doi: 10.1016/j.chest.2024.08.037. PubMed PMID: 39880301.

27. Townsend S, Newsome P, Turner AM. Presentation and prognosis of liver disease in alpha-1 antitrypsin deficiency. *Expert Rev Gastroenterol Hepatol*. 2018;12(8):745-7. Epub 20180528. doi: 10.1080/17474124.2018.1477589. PubMed PMID: 29768056.

Pre-proof

**Table 1. Clinical Characteristics of the Total Population**

	<b>Total (N=364)</b>	<b>Pi*S-het (N=148)</b>	<b>Pi*Z-het (N=149)</b>	<b>Non-S/Non-Z (N=59)</b>	<b>Pi*ZZ (N=8)</b>	<b>P-value</b>
<b>Age, years</b>	61±15	61±15	61±15	63±14	59±13	0.78
<b>Male Sex, n (%)</b>	173 (47.5%)	71 (48.0%)	68 (45.6%)	32(54.2%)	2 (25.0%)	0.40
<b>Race</b>						<.0001
<b>White, n (%)</b>	325 (89.3%)	134 (91.8%)	142 (95.3%)	42 (71.2%)	7 (87.5%)	
<b>Black, n (%)</b>	23 (6.3%)	9 (6.2%)	3 (2.0%)	11 (18.6%)	0 (0.0%)	
<b>Other, n (%)</b>	16 (4.4%)	5 (3.4%)	4 (2.7%)	6 (10.2%)	1 (12.5%)	
<b>BMI, kg/m<sup>2</sup></b>	29.3±7.9	29.5±8.1	29.7±7.7	28.4±8.2	24.5±2.5	0.16
<b>Smoking Status, n (%)</b>						0.39
<b>Never</b>	198 (55.3%)	80 (55.2%)	88 (59.9%)	26 (44.1%)	4 (57.1%)	
<b>Current</b>	51 (14.2%)	22 (15.2%)	17 (11.6%)	12 (20.3%)	0 (0.0%)	
<b>Former</b>	109 (30.4%)	43 (29.7%)	42 (28.6%)	21 (35.6%)	3 (42.9%)	
<b>Comorbidities</b>						
<b>COPD, n (%)</b>	78 (21.6%)	24 (16.3%)	34 (23.0%)	16 (27.1%)	4 (57.1%)	0.033
<b>Asthma, n (%)</b>	42 (11.6%)	22 (15.0%)	11 (7.4%)	7 (11.9%)	2 (28.6%)	0.11
<b>Bronchiectasis, n (%)</b>	46 (12.7%)	18 (12.2%)	17 (11.5%)	9 (15.3%)	2 (28.6%)	0.55
<b>Cirrhosis, n (%)</b>	138 (38.2%)	57 (38.8%)	57 (38.5%)	21 (35.6%)	3 (42.9%)	0.99
<b>Therapies</b>						
<b>Augmentation, n (%)</b>	7 (1.9%)	0 (0.0%)	5 (3.4%)	0 (0.0%)	2 (28.6%)	<.0001
<b>Supplemental O2 Use, n (%)</b>	30 (8.5%)	7 (4.8%)	13 (8.8%)	8 (13.8%)	2 (40.0%)	0.011
<b>Laboratory Values</b>						
<b>AATD Level, mg/dL</b>	116±42	135±35	94±30	150±52	13±0	<.0001
<b>WBC count, x10<sup>9</sup>/L</b>	6.6±2.2	6.7±2.0	6.4±2.1	7.1±3.0	6.0±1.9	0.36
<b>Blood neutrophil, %</b>	63±10	62±9	63±9	66±14	59±9	0.072
<b>Blood lymphocyte, %</b>	25±9	25±9	25±8	21±11	27±7	0.018
<b>Neutrophil-lymphocyte Ratio (NLR)</b>	3.3±2.8	3.0±2.0	3.0±2.0	4.9±5.0	2.4±0.9	0.021
<b>Blood eosinophil, %</b>	3±2	3±2	3±3	3±3	3±3	0.75
<b>Immunoglobulin G, mg/dL</b>	1230±526	1230±458	1200±473	1323±814	1160±234	0.93
<b>FEV1, percent predicted</b>	71±23	72±20	75±24	56±25	66±29	0.0086
<b>FEV1/ FVC</b>	0.73±0.13	0.74±0.12	0.73±0.13	0.72±0.15	0.66±0.16	0.42
<b>FEV1/ FVC &lt;0.70, n (%)</b>	42 (25.0%)	15 (26.3%)	18 (22.2%)	6 (25.0%)	3 (50.0%)	0.5

Data expressed as n (%) or mean ± standard deviation. Statistical testing by Chi-Square or Kruskal-Wallis.

**Table 2. Clinical Characteristics of the PI\*Non-S/Non-Z Variants**


	Total (N=59)	BM (N=1)	CM (N=31)	DM (N=1)	EM (N=5)	FM (N=8)	GM (N=8)	LM (N=1)	M1N (N=1)	MT (N=3)	Rare/Unknown (N=1)	P-value
Age, years	63.0 (27.0, 94.0)	54.0	62.0 (27.0, 94.0)	66.0	72.0 (57.0, 91.0)	62.0 (58.0, 82.0)	73.5 (36.0, 79.0)	33.0	49.0	66.0 (56.0, 82.0)	55.0	0.32
Male Sex, n (%)	32 (54.2%)	1 (100.0%)	18 (58.1%)	0 (0.0%)	2 (40.0%)	4 (50.0%)	3 (37.5%)	1 (100.0%)	0 (0.0%)	3 (100.0%)	1 (100.0%)	0.42
White race, n (%)	42 (71.2%)	1 (100.0%)	18 (58.1%)	1 (100.0%)	2 (40.0%)	8 (100.0%)	7 (87.5%)	1 (100.0%)	1 (100.0%)	3 (100.0%)	1 (100.0%)	0.99
BMI, kg/m <sup>2</sup>	26.4 (13.2, 46.6)	34.5	25.4 (13.2, 45.7)	25.9	26.4 (25.7, 28.5)	32.0 (19.5, 40.7)	26.3 (18.9, 46.6)	45.4	40.0	24.9 (21.2, 29.9)	unknown / not recorded	0.32
Smoking Status, n (%)												0.62
Never	26 (44.1%)	1 (100.0%)	14 (45.2%)	0 (0.0%)	3 (60.0%)	2 (25.0%)	5 (62.5%)	0 (0.0%)	0 (0.0%)	1 (33.3%)	unknown / not recorded	
Current	12 (20.3%)	0 (0.0%)	8 (25.8%)	0 (0.0%)	0 (0.0%)	1 (12.5%)	2 (25.0%)	0 (0.0%)	0 (0.0%)	1 (33.3%)	unknown / not recorded	
Former	21 (35.6%)	0 (0.0%)	9 (29.0%)	1 (100.0%)	2 (40.0%)	5 (62.5%)	1 (12.5%)	1 (100.0%)	1 (100.0%)	1 (33.3%)	unknown / not recorded	
Comorbid Conditions												
COPD, n (%)	16 (27.1%)	0 (0.0%)	11 (35.5%)	0 (0.0%)	0 (0.0%)	3 (37.5%)	1 (12.5%)	0 (0.0%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	0.67
Asthma, n (%)	7 (11.9%)	0 (0.0%)	3 (9.7%)	0 (0.0%)	1 (20.0%)	0 (0.0%)	1 (12.5%)	0 (0.0%)	1 (100.0%)	1 (33.3%)	0 (0.0%)	0.22
Bronchiectasis, n (%)	9 (15.3%)	0 (0.0%)	4 (12.9%)	0 (0.0%)	2 (40.0%)	0 (0.0%)	2 (25.0%)	0 (0.0%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	0.65
Cirrhosis, n (%)	21 (35.6%)	1 (100.0%)	9 (29.0%)	1 (100.0%)	1 (20.0%)	5 (62.5%)	2 (25.0%)	1 (100.0%)	0 (0.0%)	1 (33.3%)	1 (100.0%)	0.26
Therapies												
Supplemental O2 Use, n (%)	8 (13.8%)	0 (0.0%)	7 (23.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (33.3%)	0	0.51
Augmentation, n (%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0	n/a
Laboratory Values												
AATD Level; mg/dL	140.5 (72.0, 284.0)	72.0	187.0 (74.0, 284.0)	138.0	146.0 (138.0, 154.0)	145.0 (107.0, 222.0)	131.5 (93.0, 154.0)	83.0	unknown / not recorded	139.0 (113.0, 165.0)	49.0	0.35
WBC count, x10 <sup>9</sup> /L	6.7 (2.9, 22.0)	5.9	6.8 (4.3, 10.0)	3.2	7.1 (5.0, 9.1)	7.0 (2.9, 22.0)	5.7 (3.7, 15.1)	9.9	10.4	6.5 (3.2, 12.4)	unknown / not recorded	0.34

Blood neutrophil, percent	67.0 (31.0, 93.0)	81.0 (81.0, 81.0)	73.5 (41.0, 90.0)	56.0 (56.0, 56.0)	54.0 (50.0, 93.0)	63.5 (35.0, 72.0)	66.0 (31.0, 74.0)	67.0 (67.0, 67.0)	66.0 (66.0, 66.0)	59.0 (58.0, 69.0)	unknown / not recorded	0.18
Blood lymphocyte, percent	19.5 (3.0, 52.0)	8.0 (8.0, 8.0)	16.0 (5.0, 39.0)	36.0 (36.0, 36.0)	24.0 (3.0, 33.0)	24.5 (16.0, 52.0)	23.0 (7.0, 47.0)	19.0 (19.0, 19.0)	18.0 (18.0, 18.0)	26.0 (19.0, 32.0)	unknown / not recorded	0.4
Neutrophil-lymphocyte Ratio (NLR)	3.4 (0.7, 31.0)	10.1 (10.1, 10.1)	4.5 (1.1, 18.0)	1.6 (1.6, 1.6)	2.7 (1.6, 31.0)	2.7 (0.7, 4.5)	2.9 (0.8, 4.4)	3.5 (3.5, 3.5)	3.7 (3.7, 3.7)	2.3 (1.8, 3.6)	unknown / not recorded	0.35
Blood eosinophil, percent	2.0 (0.0, 16.0)	2.0 (2.0, 2.0)	1.5 (0.0, 8.0)	2.0 (2.0, 2.0)	2.0 (0.0, 16.0)	4.0 (2.0, 5.0)	1.5 (0.0, 4.0)	4.0 (4.0, 4.0)	9.0 (9.0, 9.0)	1.0 (0.0, 5.0)	unknown / not recorded	0.091
Immunoglobulin G, mg/dL	347.0 (56.0, 1193.0)	unknown / not recorded	262.0 (56.0, 603.0)	unknown / not recorded	229.0 (229.0, 229.0)	472.0 (310.0, 1193.0)	362.0 (146.0, 590.0)	357.0 (357.0, 357.0)	253.0 (253.0, 253.0)	375.0 (375.0, 375.0)	unknown / not recorded	
Spirometry												
FEV1, percent predicted	61 (14, 94)	unknown / not recorded	49 (14, 93)	unknown / not recorded	71 (67, 85)	81.5 (68, 95)	61.2 (44, 90)	32 (32, 32)	83 (83, 83)	64 (64, 64)	unknown / not recorded	0.091
FEV1/ FVC	0.75 (0.28, 0.92)	unknown / not recorded	0.75 (0.28, 0.92)	unknown / not recorded	0.72 (0.65, 0.74)	0.77 (0.74, 0.79)	0.79 (0.63, 0.84)	0.82 (0.82, 0.82)	0.78 (0.78, 0.78)	0.64 (0.64, 0.64)	unknown / not recorded	0.65
FEV1/ FVC <0.70, n (%)	6 (25.0%)	unknown / not recorded	3 (25.0%)	unknown / not recorded	1 (33.3%)	0 (0.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	unknown / not recorded	0.62
Outcomes Measures												
Moderate Exacerbation, n (%)	4 (6.8%)	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)	0 (0.0%)	0 (0.0%)	1 (33.3%)	unknown / not recorded	0.31
Hospitalization, n (%)	16 (27.6%)	0 (0.0%)	13 (41.9%)	0 (0.0%)	1 (20.0%)	0 (0.0%)	2 (25.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	unknown / not recorded	0.28
ICU, n (%)	9 (15.3%)	0 (0.0%)	8 (25.8%)	0 (0.0%)	1 (20.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	unknown / not recorded	0.55
Death, n (%)	15 (25.4%)	1 (100.0%)	9 (29.0%)	0 (0.0%)	3 (60.0%)	0 (0.0%)	1 (12.5%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	unknown / not recorded	0.073


Data expressed as n (%) or mean ± standard deviation. Statistical testing by Chi-Square or Kruskal-Wallis.

**Figure Legends.**

**Figure 1. Alpha-1 Antitrypsin PI\*Typing.** A) Numbers of tests by ordering location between 2016 and 2021; B) Summary distribution of PI\*type results.



**Figure 2. FEV1 Percent Predicted for PI\*Types Stratified by Smoking Status.**



FEV1 Percent Predicted by PI\*Type Groups and Smoking Status. Generalized linear models were used for modeling FEV1pp with PI\*Type and smoking status. There were statistically significant differences across PI\*types with lowest FEV1pp in the PI\*Non-S/Non-Z group that were current smokers

**Figure 3. Health Care Utilization and Mortality by PI\*Type.** A) Outpatient acute respiratory events; B) hospitalization for acute respiratory events; C) ICU admissions; D) mortality. \* $p < 0.05$  by Chi-Square testing.

